Targeted Strategies for Today's Evolving Markets

MissionIR Blog

ARCA biopharma (ABIO) Presents at Rodman & Renshaw Conference

ARCA biopharma, Inc. (NASDAQ: ABIO) is dedicated to the development of genetically-targeted therapies for cardiovascular diseases. The company’s lead product candidate, bucindolol, is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed to treat atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to bucindolol, giving it the potential to be the first genetically-targeted preventative treatment for atrial fibrillation. The U.S. Food and Drug Administration has designated the investigation of bucindolol for the treatment of atrial fibrillation as a fast track development program. For more information, visit the company’s website at

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. For more information on Rodman & Renshaw, visit
This entry was posted in Rodman and Renshaw Conference. Bookmark the permalink.

Comments are closed.